New
Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
Advertisement
Advertisement
IBRNvsETF 2ETF Comparison
ETF 2
Choose a second ETF to run a side-by-side ETF comparison with IBRN, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
IBRN performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 03/13/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | IBRN ETF 2 | -1.68%– | -3.49%– | -3.99%– | +33.62%– | +33.39%– | n/a– |
| Flows | IBRN ETF 2 | -– | -– | -– | -– | -$1M– | -– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | IBRN ETF 2 | +25.54%– | +28.24%– | +24.22%– | n/a– |
| Max drawdown | IBRN ETF 2 | -8.08%– | -23.45%– | -34.98%– | n/a– |
| Max drawdown duration | IBRN ETF 2 | 50d– | 148d– | 338d– | n/a– |
Trading data
IBRN | ETF 2 | |
Last sale 3/13/2026 at 1:30 PM | $31.00 | – |
| Previous close 03/12/2026 | $31.55 | – |
| Consolidated volume 03/12/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of February 27, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
IBRN | ETF 2 | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 3/13/2026 at 1:30 PM
Live
Closed
IBRN | ETF 2 | |
|---|---|---|
| Last price | $31.00 | – |
| 1D performance | -1.73% | – |
| AuM | $4.65 M | – |
| E/R | 0.47% | – |
Characteristics
IBRN | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | iShares | – |
| Benchmark | NYSE FactSet Global Neuro Biopharma and MedTech Index | – |
| N° of holdings | 46 | – |
| Asset class | Equities | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | August 24, 2022 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
IBRN
USA
70.96%
Ireland
7.75%
Other
21.29%
ETF 2
Sectors
IBRN
Health Care
75.49%
Other
24.51%
ETF 2
Advertisement
Diversification
IBRN
Total weight of top 15 holdings out of 15
57.3%
ETF 2
–
Top 15 holdings
Data as of January 31, 2026
IBRN
US74006W2070
4.97%
AXSOME THERA CMN STK
4.86%
ALKERMES
4.63%
SCHOLAR ROCK HOLDING CORP
3.91%
PTC THERAPEUTI/D
3.88%
BIOGEN INC
3.81%
US04016X1019
3.68%
ACADIA PHARMACEUTICALS
3.67%
DENALI THERAPEUTICS INC
3.64%
XENON PHARMACEUTICALS
3.64%
CATALYST PHARMACEUTICALS INC
3.53%
NEUROCRINE BIOSCIENCES
3.48%
SUPERNUS PHARMACEUTICALS
3.46%
US1523091007
3.10%
SK BIOPHARMACEUTICALS CO LTD
3.05%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Advertisement
Advertisement
The Active Trader Report
Active Trader Report: Use of Leveraged & Inverse ETFs Way Up
Direxion partnered with Compound Insights and Vanda to explore what’s driving the evolution of active trading — and how active traders are using leveraged and inverse funds across equities, single stocks, commodities, and volatility.
